The CIPHER trial, sponsored by Shahid Baba at the University of Louisville, is investigating the efficacy of carnosine supplementation in enhancing walking ability among patients with PAD. Given the prevalence of PAD and the limited treatment options available, a successful outcome could position carnosine as a novel therapeutic intervention in this space. The market for PAD treatments is significant, with increasing demand for effective management strategies. Competitive analysis indicates that while there are existing pharmacological treatments, none specifically target the metabolic pathways influenced by carnosine. This trial could provide a unique selling proposition if successful, potentially leading to partnerships or licensing opportunities with larger pharmaceutical companies. Diligence should focus on the safety profile of carnosine and its regulatory pathway, as well as the potential for market exclusivity based on trial outcomes.